Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile lidocaine hydrochloride/ cetylpyridinium chloride teething gel

Clinical medicine profile

lidocaine hydrochloride/ cetylpyridinium chloride teething gel

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [From component Lidocaine [Lignocaine]] Known hypersensitivity to the amide-type local anesthetics
  • patients with Adams-Stokes syndrome or with severe degrees of SA, AV, or intraventricular heart block in the absence of an artificial pacemaker.

Precautions

  • [From component Lidocaine [Lignocaine]] ECG monitoring is necessary during its IV administration
  • liver disease, con- gestive heart failure, marked hypoxia, severe respiratory depression, hypovolemia, or shock
  • administering lidocaine to patients with sinus bradycardia or incomplete heart block for the treatment of ventricular premature contractions without prior acceleration of heart rate
  • fibrillation.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

A small amount of gel is put on a clean fingertip or cotton wool pad and rubbed gently on to baby's gums. This is repeated after 20 minutes if required.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
  • Teething pain in babies

Adverse effects

  • [From component Lidocaine [Lignocaine]] Serious side effects are uncommon.
  • Drowsiness
  • dizziness
  • disorientation
  • confusion
  • lightheadedness
  • psychosis
  • apprehension
  • tinnitus
  • visual disturbances including amblyopia or diplopia
  • vomiting
  • paraesthesia
  • sensations of heat, cold, or numbness
  • difficulty swallowing
  • Fixed-dose/multi-ingredient product.
  • Clinical details partially inherited from component monographs: Lidocaine [Lignocaine].
  • Confirm combination SmPC for exact dosing.
04 Pharmacology

Mechanism & disposition

It has a local anesthetic action that relieves pain and soothes the gums.

It has a local anesthetic action that reli…Mechanism is agent-specific.At receptor, enzyme, ion channel, transpor…
Read complete mechanism

It has a local anesthetic action that relieves pain and soothes the gums. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[lidocaine] [Lidocaine] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Aminoacridine Mouth] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

[lidocaine] [Lidocaine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Aminoacridine Mouth] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Component monographs (multi-source pipeline); Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewed14 Aug 2026
EvidenceGeneral guidance

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.